Published in Semin Dial on December 05, 2008
Mechanisms of anemia in CKD. J Am Soc Nephrol (2012) 1.91
Standards of clinical practice for renal pharmacists. Can J Hosp Pharm (2013) 0.75
Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med (1998) 11.58
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet (2003) 11.47
Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med (2006) 10.65
Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol (2006) 5.56
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol (2005) 4.82
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55
Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience (1997) 2.25
Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res (2001) 1.74
Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci (2006) 0.98
Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis (2005) 0.93
Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat. Surgery (2008) 0.92
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst (2007) 4.97
Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol (2002) 4.69
High rates of adverse drug events in a highly computerized hospital. Arch Intern Med (2005) 4.68
Low literacy impairs comprehension of prescription drug warning labels. J Gen Intern Med (2006) 4.01
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol (2007) 3.85
The association of health literacy with cervical cancer prevention knowledge and health behaviors in a multiethnic cohort of women. Am J Obstet Gynecol (2002) 3.63
Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol (2005) 3.38
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol (2009) 3.26
Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst (2006) 3.23
Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med (2008) 3.07
Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg (2009) 3.07
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05
Social stigma concerns and HIV medication adherence. AIDS Patient Care STDS (2006) 3.02
Unintended consequences of health information technology: evidence from veterans affairs colorectal cancer oncology watch intervention. J Clin Oncol (2012) 2.67
Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 2.43
Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol (2004) 2.33
The financial burden of cancer: estimates from a study of insured women with breast cancer. J Support Oncol (2004) 2.30
Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am (2013) 2.29
Colorectal cancer screening knowledge, attitudes, and beliefs among veterans: does literacy make a difference? J Clin Oncol (2004) 2.27
Literacy, self-efficacy, and HIV medication adherence. Patient Educ Couns (2006) 2.18
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol (2009) 2.16
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol (2010) 2.16
The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol (2002) 2.10
Health care provider-directed intervention to increase colorectal cancer screening among veterans: results of a randomized controlled trial. J Clin Oncol (2005) 2.10
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Development and validation of a short-form, rapid estimate of adult literacy in medicine. Med Care (2007) 2.04
The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol (2013) 1.97
Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening. J Clin Oncol (2007) 1.91
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist (2007) 1.78
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke (2004) 1.78
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73
Low-dose total body irradiation followed by allogeneic lymphocyte infusion may induce remission in patients with refractory hematologic malignancy. Blood (2002) 1.70
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol (2011) 1.65
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract (2012) 1.63
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA (2006) 1.59
Literacy, race, and PSA level among low-income men newly diagnosed with prostate cancer. Urology (2006) 1.57
Post-cardiac catheterization access site complications and low-molecular -weight heparin following cardiac catheterization. J Invasive Cardiol (2003) 1.55
Legal, financial, and public health consequences of HIV contamination of blood and blood products in the 1980s and 1990s. Ann Intern Med (2002) 1.54
Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol (2002) 1.54
Finishing the picture: problems with public reporting of clinical trials. J Clin Oncol (2013) 1.52
Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol (2012) 1.51
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol (2003) 1.50
Czech health two decades on from the Velvet Revolution. Lancet (2009) 1.49
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. Ann Intern Med (2002) 1.45
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol (2004) 1.44
Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission. J Clin Oncol (2013) 1.41
Colorectal cancer screening among African-American and white male veterans. Am J Prev Med (2005) 1.39
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol (2009) 1.39
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res (2006) 1.36
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers. Arch Intern Med (2007) 1.34
Patient preferences in prostate cancer: a clinician's guide to understanding health utilities. Clin Prostate Cancer (2005) 1.33
Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer (2010) 1.28
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica (2010) 1.27
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans. J Clin Oncol (2005) 1.27
A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer (2010) 1.25
Surgical outcomes of patients with gastric carcinoma: the importance of primary tumor location and microvessel invasion. Surgery (2003) 1.24
Association of fetal hormone levels with stem cell potential: evidence for early life roots of human cancer. Cancer Res (2005) 1.21
Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project. Cancer (2006) 1.19
Development of a brief survey on colon cancer screening knowledge and attitudes among veterans. Prev Chronic Dis (2005) 1.13
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol (2009) 1.13
Marrow stem cells shift gene expression and engraftment phenotype with cell cycle transit. J Exp Med (2003) 1.12
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol (2008) 1.10
Prediction rule for atrial fibrillation after major noncardiac thoracic surgery. Ann Thorac Surg (2005) 1.10
Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw (2012) 1.10
Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol (2013) 1.06
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.06
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood (2002) 1.05
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int (2011) 1.03
Distribution of skin type and skin cancer in organ transplant recipients. Arch Dermatol (2010) 1.03
Multifunctional skin-like electronics for quantitative, clinical monitoring of cutaneous wound healing. Adv Healthc Mater (2014) 1.02
A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol (2012) 1.02
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int (2013) 1.01
A specific heptapeptide from a phage display peptide library homes to bone marrow and binds to primitive hematopoietic stem cells. Stem Cells (2004) 1.00
Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared? J Clin Oncol (2009) 1.00
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl (2009) 1.00
Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol (2007) 1.00
Acting on imperfect evidence: How much regret are we ready to accept? J Clin Oncol (2005) 0.99
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol (2007) 0.99
Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.98
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care. Oncologist (2007) 0.98
Improving mammography screening among the medically underserved. J Gen Intern Med (2013) 0.98
Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol (2011) 0.98
Systematic review of piperacillin-induced neutropenia. Drug Saf (2007) 0.97